Ovarian cancer is the second most common gynecological cancer in women in the United States. In 2022, 324,603 new cases were diagnosed globally and there were 206,956 deaths. The American Cancer Society (ACS) estimates that 21,010 new ovarian cancers will be diagnosed in the United States in 2026, and 12,450 women will die of this disease. The Ovarian Specialized Programs of Research Excellence (SPORE) was created in 1999 and has advanced our knowledge of ovarian cancer. We have gained new insights into the origins of cancer, and we have learned how to utilize these insights and test novel ideas. Research areas now cover a broader scope. Early detection, imaging technologies, risk assessment, and therapeutic approaches are being studied. Through collaboration, the ovarian SPORE researchers share expertise and ideas, and help with the clinical accrual of patients.
Mayo Clinic Ovarian Cancer SPORE
University of Pittsburgh Ovarian Cancer SPORE